FAC                                                 breast(25,26)
 _________________________________________________________________
  fluorouracil.... 500 mg/sqm IV days 1 and 8.
  adriamycin...... 50 mg/sqm IV day 1.
  cytoxan......... 500 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 21 days.

   25. Blumenschein G, et.al. FAC chemotherapy for breast cancer. 
       Proc Am Soc Clin Oncol 15:193, 1974.

  reference...
    Hortobagyi GN.  Gutterman JU.  Blumenschein GR.  Tashima CK. 
    Burgess MA.  Einhorn L.  Buzdar AU.  Richman SP.  Hersh EM. 
    Combination chemoimmunotherapy of metastatic breast cancer 
    with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. 
    Cancer.  43(4):1225-33, 1979 Apr. 
  abstract...
    One hundred and five patients with metastatic breast cancer 
    were treated with 5-fluorouracil, Adriamycin, cyclophosphamide 
    and BCG (FAC-BCG). The results were compared to those observed 
    in a group of 44 patients treated with FAC chemotherapy alone. 
    Although the overall response rates were similar (76% for 
    FAC-BCG and 73% for FAC), the duration of remission was of 9 
    months for FAC and 14 months for FAC-BCG (p = 0.04). 
    Similarly, survival or responding patients treated with 
    FAC-BCG was significantly longer (24 months) than that 
    observed in the chemotherapy alone treated group (15 months). 
    There was no difference in survival or duration on study for 
    non-responders. Response rates were not influenced by dominant 
    site of disease, menopausal status or disease-free interval. 
    The duration of remission and survival, however, were 
    significantly longer for patients with bone and soft tissue 
    involvement than for patients with visceral metastasis. 
    Similarly patients with 1 or 2 metastatic sites survived 
    significantly longer than those with more than 3 organ sites 
    involved (p = 0.02). This chemotherapeutic combination is 
    highly effective in inducing remissions. In addition, 
    nonspecific immunotherapy with BCG appears to prolong duration 
    of remission and survival for responding patients.